The DOI matches its Crossref record, with a small difference in title or year; 25 of the 26 references it cites were found in a registry or an index.
Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium
Open accessAbstract
Background Sorafenib, an inhibitor of B-raf, VEGFR2, and PDGFR-β, has activity against pancreatic cancer in preclinical models. In a phase I trial of gemcitabine plus sorafenib, 57% of pancreatic cancer patients achieved stable disease.Patients and methods We conducted a multi-center phase II trial of sorafenib plus gemcitabine in chemo-naïve patients with histologically-confirmed, advanced pancreatic cancer. Patients received sorafenib 400 mg twice daily and gemcitabine 1,000 mg/m(2) on days 1, 8 and 15 of a 28 day cycle.Results Seventeen patients enrolled at 4 centers; 13 were evaluable for response. There were no objective responses; 18% had stable disease. Median overall survival was 4.0 months (95% CI: 3.4, 5.9); median progression-free survival was 3.2 months (95% CI: 1.6, 3.6). Grade 3/4 toxicities included thrombosis in 18% of patients, dehydration or hand-foot syndrome in 12%, and hypertension or gastrointestinal bleeding in 6%.Conclusion Gemcitabine plus sorafenib is inactive in advanced pancreatic cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“To date, Src inhibitors as monotherapy have not yielded promising results [46, 47].”
From Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src (2016) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,895
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D. P., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P. W., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,060
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Wilhelm, S. M., Adnane, L., Newell, P. H., Villanueva, A., Llovet, J. M., & Lynch, M. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0013 · Cited by 1,462
A Confidence Interval for the Median Survival Time
Brookmeyer, R., & Crowley, J. (1982) · Biometrics · doi:10.2307/2530286 · Cited by 914
Research works printed but not linked: 1
- Kindler HL, Ioka T, Richel DJ et al (2009) A double-blinded, placebo-controlled, randomised, phase III study of axitinib (AG-013736) plus gemcitabine versus placebo in advanced pancreatic cancer patients. Eur J Cancer Suppl 7(361):6502
Cited by
Sorted by citations
Items 101–103 of 103
Zheng, Y., Zhou, Y., Xia, H., Liang, W., Wei, X., & Zhou, J. (2025) · Gastrointestinal Tumors · doi:10.48130/git-0025-0001
Voogd, D. W. M., Lucassen, M. J. J., van der Noll, R., Zielhuis, S. W. J., Boss, D. S., Beijnen, J. H., Rosing, H., Tibben, M. M., Huitema, A. D. R., Schellens, J. H. M., et al. (2025) · Oncology and Therapy · doi:10.1007/s40487-025-00340-8
Liu, Q., Li, R., Wu, H., & Liang, Z. (2023) · Figshare · doi:10.6084/m9.figshare.22619240
Metadata
- Authors
- Kindler, H. L., Wroblewski, K., Wallace, J. A., Hall, M. J., Locker, G., Nattam, S., Agamah, E., Stadler, W. M., & Vokes, E. E.
- Affiliations
- University of Chicago (US)
- Endeavor Health (US)
- Fort Wayne Medical Institute (US)
- Corresponding author
- Kindler, Hedy Lee
- ORCID
- Venue
- Investigational New Drugs
- Published
- 2010-08-28
- Volume
- 30
- Issue
- 1
- Pages
- 382-386
- ISSN
- 0167-6997 (ISSN-L)
- 1573-0646
- PMC
- PMC4319645
- OpenAlex
- W2061953474
- Cited by
- 103
- References
- 26
- Citations by year
- 2025: 2 · 2024: 3 · 2023: 7 · 2022: 6 · 2021: 8 · 2020: 6 · 2019: 6 · 2018: 8 · 2017: 6 · 2016: 6 · 2015: 8 · 2014: 7 · 2013: 12 · 2012: 9
- FWCI
- 4.74
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Investigational New Drugs (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (n01cm62201-16-0-1)
- National Cancer Institute (N01 CM062201, N01 CM-62201)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- gemcitabine, sorafenib, advanced pancreatic cancer, combination chemotherapy, VEGFR-2 inhibition, chemotherapy-naive patients, stable disease, thrombosis, hand-foot syndrome, overall survival, progression-free survival
- MeSH terms
- Sorafenib, Gemcitabine, Adenocarcinoma, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Benzenesulfonates, Chicago, Deoxycytidine, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Niacinamide, Pancreatic Neoplasms, Phenylurea Compounds, Pyridines, Time Factors, Universities, Treatment Outcome, Disease-Free Survival, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
